Otonomy Inc  

(Public, NASDAQ:OTIC)   Watch this stock  
Find more results for otic
5.05
+0.05 (1.00%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.00 - 5.20
52 week 2.80 - 21.15
Open 5.00
Vol / Avg. 1.33M/1.81M
Mkt cap 154.73M
P/E     -
Div/yield     -
EPS -3.23
Shares 30.34M
Beta 3.33
Inst. own 70%
Nov 29, 2017
Otonomy Inc at Piper Jaffray Healthcare Conference
Nov 8, 2017
Q3 2017 Otonomy Inc Earnings Call
Nov 8, 2017
Q3 2017 Otonomy Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -7446.10% -16190.78%
Operating margin -7559.22% -16322.25%
EBITD margin - -16218.59%
Return on average assets -54.75% -55.07%
Return on average equity -59.63% -59.09%
Employees 139 -
CDP Score - -

Address

4796 Executive Dr
SAN DIEGO, CA 92121-3090
United States - Map
+1-619-3232200 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.

Officers and directors

Jay Lichter Ph.D. Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
David A. Weber Ph.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Paul E. Cayer Chief Financial and Business Officer
Age: 55
Bio & Compensation  - Reuters
Robert Michael Savel II Chief Technical Officer
Age: 49
Bio & Compensation  - Reuters
Kathie M. Bishop Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Eric J. Loumeau Chief Compliance Officer, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
Dean Hakanson M.D. Chief Medical Officer
Age: 65
Bio & Compensation  - Reuters
Vickie L. Capps Independent Director
Age: 55
Bio & Compensation  - Reuters
Iain R. McGill Independent Director
Age: 44
Bio & Compensation  - Reuters
George J. Morrow Independent Director
Age: 65
Bio & Compensation  - Reuters